Literature DB >> 23399421

Effectiveness of seasonal 2012/13 vaccine in preventing laboratory-confirmed influenza infection in primary care in the United Kingdom: mid-season analysis 2012/13.

J McMenamin1, N Andrews, C Robertson, Dm Fleming, H Durnall, B von Wissmann, J Ellis, A Lackenby, S Cottrell, B Smyth, M Zambon, C Moore, Jm Watson, Rg Pebody.   

Abstract

The early experience of the United Kingdom (UK) is that influenza B has dominated the influenza 2012/13 season. Overall trivalent influenza vaccine (TIV) adjusted vaccine effectiveness (VE) against all laboratory-confirmed influenza in primary care was 51% (95% confidence interval (CI): 27% to 68%); TIV adjusted VE against influenza A alone or influenza B alone was 49% (95% CI: -2% to 75%) and 52% (95% CI: 23% to 70%) respectively. Vaccination remains the best protection against influenza.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23399421     DOI： 10.2807/ese.18.05.20393-en

Source DB:  PubMed          Journal:  Euro Surveill        ISSN： 1025-496X


  9 in total

1.  Effectiveness of 2012-2013 influenza vaccine against influenza-like illness in general population: estimation in a French web-based cohort.

Authors:  Marion Debin; Vittoria Colizza; Thierry Blanchon; Thomas Hanslik; Clement Turbelin; Alessandra Falchi
Journal:  Hum Vaccin Immunother       Date:  2013-12-16       Impact factor: 3.452

2.  Measurement of Vaccine Direct Effects Under the Test-Negative Design.

Authors:  Joseph A Lewnard; Christine Tedijanto; Benjamin J Cowling; Marc Lipsitch
Journal:  Am J Epidemiol       Date:  2018-12-01       Impact factor: 4.897

3.  Haemagglutinin mutations and glycosylation changes shaped the 2012/13 influenza A(H3N2) epidemic, Houston, Texas.

Authors:  K M Stucker; S A Schobel; R J Olsen; H L Hodges; X Lin; R A Halpin; N Fedorova; T B Stockwell; A Tovchigrechko; S R Das; D E Wentworth; J M Musser
Journal:  Euro Surveill       Date:  2015-05-07

4.  Effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2013.

Authors:  N Turner; N Pierse; A Bissielo; Qs Huang; S Radke; Mg Baker; Ma Widdowson; H Kelly
Journal:  Euro Surveill       Date:  2014-08-28

5.  A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.

Authors:  Louise Roggelin; Christof D Vinnemeier; Seetha Meyer; Kai Witte; Lydia Marx; Wiebke Theeß; Gerd D Burchard; Thierry Rolling; Jakob P Cramer
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Influenza vaccine effectiveness assessment through sentinel virological data in three post-pandemic seasons.

Authors:  Núria Torner; Ana Martínez; Luca Basile; M Angeles Marcos; Andrés Antón; M Mar Mosquera; Ricard Isanta; Carmen Cabezas; Mireia Jané; Angela Domínguez; The Pidirac Sentinel Surveillance Program Of Catalonia
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

7.  Effectiveness and knowledge, attitudes and practices of seasonal influenza vaccine in primary healthcare settings in South Africa, 2010-2013.

Authors:  Johanna M McAnerney; Sibongile Walaza; Adam L Cohen; Stefano Tempia; Amelia Buys; Marietjie Venter; Lucille Blumberg; Jazmin Duque; Cheryl Cohen
Journal:  Influenza Other Respir Viruses       Date:  2015-05       Impact factor: 4.380

8.  2012-2013 Seasonal influenza vaccine effectiveness against influenza hospitalizations: results from the global influenza hospital surveillance network.

Authors:  Joan Puig-Barberà; Angels Natividad-Sancho; Odile Launay; Elena Burtseva; Meral A Ciblak; Anita Tormos; Amparo Buigues-Vila; Sergio Martínez-Úbeda; Anna Sominina
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

9.  Interim adjusted estimates of seasonal influenza vaccine effectiveness - United States, February 2013.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-02-22       Impact factor: 17.586
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.